Orgenesis Inc. (ORGS)

NASDAQ: ORGS · IEX Real-Time Price · USD
0.822
-0.028 (-3.29%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide.

The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.

It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient.

The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011.

Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Orgenesis Inc.
Orgenesis logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 167
CEO Ms. Vered Caplan M.Sc.

Contact Details

Address:
20271 Goldenrod Lane
Germantown, Maryland 20876
United States
Phone (480) 659-6404
Website orgenesis.com

Stock Details

Ticker Symbol ORGS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001460602
CUSIP Number 68619K204
ISIN Number US68619K2042
Employer ID 98-0583166
SIC Code 2834

Key Executives

Name Position
Vered Caplan M.Sc. Chairperson of the Board, Chief Executive Officer and President
Prof. Sarah Ferber Ph.D. Founder and Chief Scientific Officer
Victor Miller Chief Financial Officer
Pierre Lammeretz Interim Chief Operating Officer
Dr. Shimon Hassin Ph.D. Chief Technology Officer
Evan Fishman Chief Financial Officer of Orgenesis Biotech
Joseph Carpinelli Chief Financial Officer of Octomera

Latest SEC Filings

Date Type Title
Mar 27, 2024 8-K Current Report
Mar 14, 2024 D Notice of Exempt Offering of Securities
Mar 7, 2024 8-K Current Report
Mar 1, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K Current Report
Jan 24, 2024 8-K Current Report
Jan 22, 2024 8-K Current Report
Jan 5, 2024 8-K Current Report
Dec 29, 2023 8-K Current Report